# Dupilumab in the Treatment of Severe Uncontrolled CRSwNP: a Multicentre Observational Real-life Study (DUPIREAL)

> **NCT05529784** · — · UNKNOWN · sponsor: **Fondazione Policlinico Universitario Agostino Gemelli IRCCS** · enrollment: 600 (estimated)

## Conditions studied

- Chronic Rhinosinusitis With Nasal Polyps

## Interventions

- **DRUG:** Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]

## Key facts

- **NCT ID:** NCT05529784
- **Lead sponsor:** Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-10-06
- **Primary completion:** 2022-10-01
- **Final completion:** 2023-10-01
- **Target enrollment:** 600 (ESTIMATED)
- **Last updated:** 2023-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05529784

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05529784, "Dupilumab in the Treatment of Severe Uncontrolled CRSwNP: a Multicentre Observational Real-life Study (DUPIREAL)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05529784. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*